Limits...
Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer.

Geng Q, Fan T, Zhang B, Wang W, Xu Y, Hu H - Respir. Res. (2014)

Bottom Line: The receiver operating characteristic (ROC) curves were generated for the five miRNAs.Stratified analyses indicated that plasma miR-20a, miR-223, miR-21 and miR-145 showed better predictive value in smokers than in non-smokers, while miR-155 might be more suitable for non-smokers.Nevertheless, further validation and optimizing improvement should be performed on larger sample to confirm our results.

View Article: PubMed Central - PubMed

Affiliation: Department of Thoracic Surgery, Renmin Hospital of Wuhan University, 238 Jie Fang Rd, Wuhan, 430060, China. qinggeng@med-research.biz.

ABSTRACT

Background: In order to find novel noninvasive biomarkers with high accuracy for the screening of early-stage non-small cell lung cancer (NSCLC), we investigate the predictive power of 5 microRNAs (miR-20a, miR-145, miR-21, miR223 and miR-221) as potential biomarkers in early-stage NSCLC.

Methods: In training set, 25 early-stage NSCLC patients and 25 matched healthy controls are included to assess the miRNA expression profile between early-stage NSCLC patients and healthy controls by real-time RT-PCR. We found that five of these miRNAs (miR-20a, miR-223, miR-21, miR-221 and miR-145) levels in NSCLC patients were significantly dysregulated compared with the healthy groups and thus were selected to validation set. Therefore, a validation experiment was further performed to investigate the potential predictive power of these five miRNAs based on 126 early-stage NSCLC patients, 42 NCPD patients and 60 healthy controls. The receiver operating characteristic (ROC) curves were generated for the five miRNAs.

Results: ROC curve analyses suggested that these five plasma miRNAs could be promising biomarkers for NSCLC, with relatively high AUC values as follows: miR-20a, 0.89 with 95% CI of [0.85-0.93]; miR-223, 0.94 with 95% CI of [0.91-0.96]; miR-21, 0.77 with 95% CI of [0.71-0.83]; miR-155, 0.92 with 95% CI of [0.89-0.96]; miR-145, 0.77 with 95% CI of [0.71-0.83]. Stratified analyses indicated that plasma miR-20a, miR-223, miR-21 and miR-145 showed better predictive value in smokers than in non-smokers, while miR-155 might be more suitable for non-smokers. In addition, all of these five miRNAs could differentiate NSCLC from controls with a higher accuracy in advanced stage and squamous carcinoma subgroups.

Conclusions: In conclusion, our study suggested that five plasma miRNAs (miR-20a, miR-145, miR-21, miR-223 and miR-221) can be used as promising biomarkers in early screening of NSCLC. Nevertheless, further validation and optimizing improvement should be performed on larger sample to confirm our results.

Show MeSH

Related in: MedlinePlus

Scatter plot of expression levels (a) and Receiver operator characteristic (ROC) curve (b) analysis of plasma miR-223.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4248445&req=5

Fig2: Scatter plot of expression levels (a) and Receiver operator characteristic (ROC) curve (b) analysis of plasma miR-223.

Mentions: In validation set, we choose these five miRNAs (miR-20a, miR-223, miR-21, miR-221 and miR-145) as novel biomarkers for NSCLC screening based on 126 NSCLC patients, 42 NCPD patients and 60 healthy controls. We first pondered the predictive application of these five miRNAs by comparing the relative expression in plasma between NSCLC patients and two control groups. As shown in FiguresĀ 1, 2, 3, 4 and 5, there were different expression of these five miRNAs between NSCLC patients and healthy controls (all P < 0.001), as well as NSCLC patients and NCPD controls. However, no significant difference was observed between NCPD patients and healthy controls for miR-20a, miR-21, miR-221 and miR-145 (all P > 0.05), except for miR-223 (P < 0.01).Figure 1


Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer.

Geng Q, Fan T, Zhang B, Wang W, Xu Y, Hu H - Respir. Res. (2014)

Scatter plot of expression levels (a) and Receiver operator characteristic (ROC) curve (b) analysis of plasma miR-223.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4248445&req=5

Fig2: Scatter plot of expression levels (a) and Receiver operator characteristic (ROC) curve (b) analysis of plasma miR-223.
Mentions: In validation set, we choose these five miRNAs (miR-20a, miR-223, miR-21, miR-221 and miR-145) as novel biomarkers for NSCLC screening based on 126 NSCLC patients, 42 NCPD patients and 60 healthy controls. We first pondered the predictive application of these five miRNAs by comparing the relative expression in plasma between NSCLC patients and two control groups. As shown in FiguresĀ 1, 2, 3, 4 and 5, there were different expression of these five miRNAs between NSCLC patients and healthy controls (all P < 0.001), as well as NSCLC patients and NCPD controls. However, no significant difference was observed between NCPD patients and healthy controls for miR-20a, miR-21, miR-221 and miR-145 (all P > 0.05), except for miR-223 (P < 0.01).Figure 1

Bottom Line: The receiver operating characteristic (ROC) curves were generated for the five miRNAs.Stratified analyses indicated that plasma miR-20a, miR-223, miR-21 and miR-145 showed better predictive value in smokers than in non-smokers, while miR-155 might be more suitable for non-smokers.Nevertheless, further validation and optimizing improvement should be performed on larger sample to confirm our results.

View Article: PubMed Central - PubMed

Affiliation: Department of Thoracic Surgery, Renmin Hospital of Wuhan University, 238 Jie Fang Rd, Wuhan, 430060, China. qinggeng@med-research.biz.

ABSTRACT

Background: In order to find novel noninvasive biomarkers with high accuracy for the screening of early-stage non-small cell lung cancer (NSCLC), we investigate the predictive power of 5 microRNAs (miR-20a, miR-145, miR-21, miR223 and miR-221) as potential biomarkers in early-stage NSCLC.

Methods: In training set, 25 early-stage NSCLC patients and 25 matched healthy controls are included to assess the miRNA expression profile between early-stage NSCLC patients and healthy controls by real-time RT-PCR. We found that five of these miRNAs (miR-20a, miR-223, miR-21, miR-221 and miR-145) levels in NSCLC patients were significantly dysregulated compared with the healthy groups and thus were selected to validation set. Therefore, a validation experiment was further performed to investigate the potential predictive power of these five miRNAs based on 126 early-stage NSCLC patients, 42 NCPD patients and 60 healthy controls. The receiver operating characteristic (ROC) curves were generated for the five miRNAs.

Results: ROC curve analyses suggested that these five plasma miRNAs could be promising biomarkers for NSCLC, with relatively high AUC values as follows: miR-20a, 0.89 with 95% CI of [0.85-0.93]; miR-223, 0.94 with 95% CI of [0.91-0.96]; miR-21, 0.77 with 95% CI of [0.71-0.83]; miR-155, 0.92 with 95% CI of [0.89-0.96]; miR-145, 0.77 with 95% CI of [0.71-0.83]. Stratified analyses indicated that plasma miR-20a, miR-223, miR-21 and miR-145 showed better predictive value in smokers than in non-smokers, while miR-155 might be more suitable for non-smokers. In addition, all of these five miRNAs could differentiate NSCLC from controls with a higher accuracy in advanced stage and squamous carcinoma subgroups.

Conclusions: In conclusion, our study suggested that five plasma miRNAs (miR-20a, miR-145, miR-21, miR-223 and miR-221) can be used as promising biomarkers in early screening of NSCLC. Nevertheless, further validation and optimizing improvement should be performed on larger sample to confirm our results.

Show MeSH
Related in: MedlinePlus